Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease (DED)

A Phase 3 Multi-Center, Randomized, Double Masked, Vehicle Controlled Study to Assess the Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease (DED)

A Phase 3 Multi-Center, Randomized, Double Masked, Vehicle Controlled Study to Assess the Safety and Efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed with Dry Eye Disease (DED)

Study Overview

• Status: Recruiting
• Conditions: Dry Eye Disease
• Intervention / Treatment: Drug: Vehicle; Drug: ST-100 (vezocolmitide)

• Study Type: Interventional
• Enrollment (Estimated): 175
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: George Ousler; Phone Number: 9481 9786858900; Email: gousler@oraclinical.com

Study Locations

• United States
  • Tennessee
    • Memphis, Tennessee, United States, 38119
      • Recruiting
      • Total Eye Care, PA
      • Contact: David Evans, OD; Phone Number: 901-761-4620
      • Principal Investigator: David Evans, OD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Be at least 18 years of age;
2. Provide written informed consent;
3. Have a reported history of DED for at lease 6 months prior to Visit 1;
4. Have a history of use or desire to use eye drops for DED within 6 months of Visit 1;
5. Report a score of ≥ 2 on the Ora Calibra® Ocular Discomfort & 4-symptom questionnaire in at least one symptom pre-CAE® at Visits 1 and 2;
6. Have a Schirmer's Test score of ≤ 10 mm and ≥ 1 mm at Visits 1 and 2;
7. Have a conjunctival redness score ≥ 1 according to the Ora Calibra® Conjunctival Redness for Dry Eye Scale in at least one eye at pre-CAE® Visits 1 and 2;
8. Have a corneal fluorescein staining score of ≥ 2 in at least one region (e.g. inferior, superior, or central) pre-CAE® at Visits 1 and 2;
9. Have a sum corneal fluorescein staining score of ≥ 4, based on the sum of the inferior, superior, and central regions pre-CAE®, at Visits 1 and 2;
10. Have a total lissamine green conjunctival score of ≥ 2, based on the sum of the temporal and nasal regions pre-CAE® at Visits 1 and 2;

11. Demonstrates a response to the CAE® at Visits 1 and 2 as defined by:

    Having at least a ≥1 point increase in fluorescein staining in the inferior region in at least one eye following CAE® exposure Reporting an Ora Calibra® Ocular Discomfort Score ≥ 3 at 2 or more consecutive time points in at least one eye during CAE® exposure (if a subject has an ocular discomfort rating of 3 at a time = 0 for an eye, they must report an ocular discomfort rating of 4 for two consecutive measurements for that eye). Note: a subject cannot have an ocular discomfort score of 4 at time = 0);

12. Have at lease one single eye satisfy all criteria for 6, 7, 8, 9, 10 and 11 above.

Exclusion Criteria:

1. Have any clinically significant slit lap findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction, lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;
2. Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;
3. Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study;
4. Have used any eye drops within 2 hours of Visit 1;
5. Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;
6. Have used Restasis®, Xiidra®, or Cequa® ophthalmic solutions Tyrvaya® nasal spray, or Miebo® or Xdemvy® solution within 45 days of Visit 1;
7. Have any planned ocular and/or lid surgeries over the study period or any ocular surgery within the last 6 months;
8. Have used, are using or anticipate using permanent or temporary punctal plugs during the study within 90 days of Visit 1;
9. Be currently taking any topical ophthalmic prescription (including medications for glaucoma) or over-the-counter solutions, artificial tears, gels or scrubs, or using a moisture chamber and cannot discontinue these medications for the from Visit 1 until after Visit 8 of the trial (excluding medications allowed for the conduct of the study);
10. Be currently taking or have taken Omega-3 supplements within the last 3 months;
11. Be currently taking of have taken CHANTIX® (varenicline) tablets within 6 months prior to Visit 1 that is not on a stable dose. The dose cannot change during the conduct of the study;
12. Have corrected visual acuity (VA) greater than or equal to logarithm of the Minimum Angle of Resolution (logMAR) +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit 1;
13. Be a woman who is pregnant, nursing, or planning a pregnancy during the study;
14. Be unwilling to submit a urine pregnancy test at Visit 1 and Visit 8 (or early termination visit) if of childbearing potential. Non-childbearing potential is defined as a woman who is permanently sterilized (hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least 6 months prior to dosing), or is post-menopausal (where post-menopausal is defined as no menses for 12 months without an alternative medial cause);
15. Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception includes: hormonal - oral, implantable, injectable, or transdermal contraceptives for at least one month prior to first visit; Use two of the following effective methods of contraception: intrauterine device (IUD without local hormone release), diaphragm, cervical cap, and/or condoms; or surgical sterilization of partner (i.e., a female participant's male partner has undergone effective surgical sterilization such as vasectomy before the female participant entered the clinical trial) who has obtained documentation of absence of sperm in his ejaculate and is the sole sexual partner of the female participant during the clinical trial. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use adequate birth control as defined above for the remainder of the study;
16. Have a known allergy and/or sensitivity to the Study Drug or its components;
17. Have a condition or be in a situation that the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study;
18. Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days of Visit 1;
19. Be currently using any medication known to cause ocular drying that is not used on a stable dosing regimen for the least 30 dats prior to Visit 1;
20. Have a known history of meibomian gland procedures (e.g. LipiFlow, laser peripheral iridotomy (LPI), probing, etc.) within 6 months of study enrollment;
21. Be unable or unwilling to follow instructions, including participation in all study assessments and visits;
22. Has participated in any other clinical trials of ophthalmologic drugs for 30 days before or during participation in this Study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ST-100-002; ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Bilaterally twice daily for 7 weeks (49 days)	Drug: ST-100 (vezocolmitide); ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml
Placebo Comparator: Vehicle Ophthalmic Solution; Vehicle Ophthalmic Solution Bilaterally twice daily for 7 weeks (49 days)	Drug: Vehicle; Vehicle Ophthalmic Solution

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Compare the efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution to vehicle using Schirmer's test at day 29	Proportion of responders in Schirmer's test with ≥ 10mm improvement from baseline at Day 29	29 Days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Compare the efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution to vehicle for the treatment of the signs and symptoms of DED	Ocular Discomfort scores change from baseline at day 15 as measured by Ora Calibra Ocular Discomfort Scale	15 Days
Compare the efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution to vehicle for the treatment of the signs and symptoms of DED	Pain Score change from baseline at Day 15	15 Days
Compare the efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution to vehicle for the treatment of the signs and symptoms of DED	Blurred vision score change from baseline at day 4 as measured by OSDI	4 days
Compare the efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution to vehicle for the treatment of the signs and symptoms of DED	Proportion of responders in Schirmer's Test with ≥ 10mm improvement from baseline at day 15	15 days
Assess the safety and tolerability of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution	Visual Acuity	49 days
Assess the safety and tolerability of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution	Slit-lamp evaluation	49 days
Assess the safety and tolerability of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution	Adverse event monitoring	49 days
Assess the safety and tolerability of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution	Intraocular pressure	49 days
Assess the safety and tolerability of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution	Undilated fundoscopy	49 days

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Compare the efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution to vehicle using additional measures	Fluorescein staining (Ora Calibra scale) at Visits 3, 4, 5, 6, 7, and 8: regions: central, superior, inferior, temporal, nasal, corneal sum, conjunctival sum, and total eye score	49 days
Compare the efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution to vehicle using additional measures	Lissamine green staining (Ora Calibra scale) at Visits 3, 4, 5, 6, 7, and 8: regions: central, superior, inferior, temporal, nasal, corneal sum, conjunctival sum, and total eye score	49 days
Compare the efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution to vehicle using additional measures	Tear film break-up time at Visits 3, 4, 5, 6, 7, and 8	49 days
Compare the efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution to vehicle using additional measures	Conjunctival Redness at Visits 3, 4, 5, 6, 7, and 8	49 days
Compare the efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution to vehicle using additional measures	Drop comfort assessment after randomization at Visit 2, 6, and 8	49 Days
Compare the efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution to vehicle using additional measures	Ocular Surface Disease Index (OSDI) at Visits 3, 4, 5, 6, 7, and 8	49 Days
Compare the efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution to vehicle using additional measures	Ocular Discomfort Scale at Visits 3, 4, 5, 6, 7, and 8	49 days
Compare the efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution to vehicle using additional measures	Dry Eye Disease symptom questionnaire at Visits 3, 4, 5, 6, 7, and 8	49 days
Compare the efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution to vehicle using additional measures	Blink rate at Visits 6 and 7	29 days
Compare the efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution to vehicle using additional measures	Daily Dosing Diary	49 days

Collaborators and Investigators

• Sponsor: ORA, Inc.
• Collaborators: Stuart Therapeutics, Inc.

Publications and helpful links

General Publications

• Baratta RO, Schlumpf E, Buono BJD, DeLorey S, Calkins DJ. Corneal collagen as a potential therapeutic target in dry eye disease. Surv Ophthalmol. 2022 Jan-Feb;67(1):60-67. doi: 10.1016/j.survophthal.2021.04.006. Epub 2021 Apr 18.
• Fiscella RG. Understanding dry eye disease: a managed care perspective. Am J Manag Care. 2011 Dec;17 Suppl 16:S432-9.
• Hapach LA, VanderBurgh JA, Miller JP, Reinhart-King CA. Manipulation of in vitro collagen matrix architecture for scaffolds of improved physiological relevance. Phys Biol. 2015 Dec 21;12(6):061002. doi: 10.1088/1478-3975/12/6/061002.
• Kivanany PB, Grose KC, Yonet-Tanyeri N, Manohar S, Sunkara Y, Lam KH, Schmidtke DW, Varner VD, Petroll WM. An In Vitro Model for Assessing Corneal Keratocyte Spreading and Migration on Aligned Fibrillar Collagen. J Funct Biomater. 2018 Sep 21;9(4):54. doi: 10.3390/jfb9040054.
• Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015 Jan 30;112(5):71-81; quiz 82. doi: 10.3238/arztebl.2015.0071.
• Ousler GW 3rd, Rimmer D, Smith LM, Abelson MB. Use of the Controlled Adverse Environment (CAE) in Clinical Research: A Review. Ophthalmol Ther. 2017 Dec;6(2):263-276. doi: 10.1007/s40123-017-0110-x. Epub 2017 Sep 27.
• Shetty R, Deshpande K, Deshmukh R, Jayadev C, Shroff R. Bowman Break and Subbasal Nerve Plexus Changes in a Patient With Dry Eye Presenting With Chronic Ocular Pain and Vitamin D Deficiency. Cornea. 2016 May;35(5):688-91. doi: 10.1097/ICO.0000000000000785.
• Wareham LK, Holden JM, Bossardet OL, Baratta RO, Del Buono BJ, Schlumpf E, Calkins DJ. Collagen mimetic peptide repair of the corneal nerve bed in a mouse model of dry eye disease. Front Neurosci. 2023 May 16;17:1148950. doi: 10.3389/fnins.2023.1148950. eCollection 2023.

Study record dates

Study Major Dates

• Study Start (Actual): December 29, 2023
• Primary Completion (Estimated): June 30, 2024
• Study Completion (Estimated): July 30, 2024

Study Registration Dates

• First Submitted: December 7, 2023
• First Submitted That Met QC Criteria: December 18, 2023
• First Posted (Actual): December 21, 2023

Study Record Updates

• Last Update Posted (Estimated): January 18, 2024
• Last Update Submitted That Met QC Criteria: January 16, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Lacrimal Apparatus Diseases; Keratoconjunctivitis; Conjunctivitis; Conjunctival Diseases; Keratitis; Corneal Diseases; Eye Diseases; Dry Eye Syndromes; Keratoconjunctivitis Sicca
• Other Study ID Numbers: ST-100-002

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No